Coherus BioSciences Inc.
www.coherus.com
Latest From Coherus BioSciences Inc.
Dr Reddy’s De Vré On Momentum In US Biosimilars Market, Interchangeability
The global head of Dr Reddy’s biologics business unit, Raymond De Vré, discusses in an interview with Scrip how things are looking up in the US biosimilars market, why interchangeability isn’t a major concern and how galloping volume growth is being seen by the company in emerging markets.
Apotex Mystery: Why Has Accord BioPharma Taken Its Place In US Biosimilar Pegfilgrastim Litigation?
Court grants request to substitute Accord BioPharma for Apotex in Amgen infringement suit. Apotex says it has no plans to exit the biosimilar business.
Mylan's Aflibercept Biosimilar Gets Green Light For Trials In India
Mylan’s proposal to progress studies for its aflibercept biosimilar has been endorsed by an expert panel in India, which expects availability of such biosimilars to expand access to anti-VEGF therapies.
Genentech Is Second Biologic Titan To Resolve Trade Secret Suit; Former Employees Still On Hook
Genentech reaches memorandum of understanding with JHL Biotech involving four biosimilars while continuing its suit against former employees; Amgen settlement with Coherus ended litigation entirely.
Company Information
- Industry
-
Biotechnology
- Large Molecule
-
Pharmaceuticals
- Generic Drugs
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Dermatology
- Gastrointestinal
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Ophthalmic
- Alias(es)
- BioGenerics Inc.
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Coherus BioSciences Inc.
- Senior Management
-
Dennis Lanfear, Chmn., Pres. & CEO
Jean-Frederic Viret, PhD, CFO
Vladimir Vexler, PhD, CSO
Darlene Horton, MD, CMO & Chief Reg. Affairs Officer
Vince Anicetti, COO
Erik Wiberg, VP, Corp. Dev. - Contact Info
-
Coherus BioSciences Inc.
Phone: (800) 794-5434
333 Twin Dolphin Dr., Ste. 600
Redwood City, CA 94065
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice